Skye Bioscience rises after experimental weight-loss drug shows promise in mice
ReutersApr 15, 2025 12:20 PM
Shares of drug developer Skye Bioscience SKYE.O rise 11.5% to $1.46 premarket
Co says its drug candidate, nimacimab, showed 23.5% weight loss in mice, comparable to Eli Lilly's LLY.N popular drug, tirzepatide, sold as Zepbound, and Novo Nordisk's NOVOb.CO experimental drug, monlunabant
SKYE also says nimacimab, when combined with tirzepatide, showed a greater than 30% weight loss
Initial data from SKYE's mid-stage study in obesity is expected in late Q3/early Q4 2025
Up to last close, stock had fallen 53.7% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Coca Cola (KO) Q4 Earnings Preview: Look for the Upside in the AI Initiatives, not in the Revenue and the EPS
Coca-Cola (KO) enters its fourth-quarter 2025 earnings call tomorrow with significant momentum. However, a fundamental shift is occurring.TradingKey
9 hours ago
Warsh’s Fed Era Signals a Death Knell for QE, Jolting the $30 Trillion Treasury Market
With Warsh’s nomination, his past proposals for governing the Federal Reserve are being brought to the forefront. A central issue is the formulation of a new "1951 Accord" to restructure the relationship between the Fed and the Treasury. Analysts suggest such a move could impact the $30 trillion TreTradingKey
22 hours ago
Amazon Stock Predictions for 2026 to 2030: Will They Exceed Expectations and Achieve Major Long-Term Goals?
TradingKey - As we head into 2026, many investors are questioning where Amazon (AMZN) fits into the technology world.TradingKey
Fri, Feb 6
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.TradingKey
Fri, Feb 6
